Dr. Yailin Rios praised today the development of Cuban science seen through the application of the medicine Heberprot-P in patients with diabetic foot ulcers in Venezuela.
According to Rios, who is a specialist in angiology and vascular surgery, the possibility of benefiting the Venezuelans with one of the flagship medicines of the Cuban biotechnology, the recombinant human epidermal growth factor is a privilege.
In dialogue with Prensa Latina, the technical coordinator of the Good Living for Diabetics Program highlighted that the efficacy in using this drug in patients with a satisfactory response to the treatment reflects the positive impact of the project.
The Cuban collaborator, who favors health preventive and promotional actions, explained the importance of this function to achieve an early diagnosis of injuries and avoid invasive procedures.
Cuban angiologists and vascular surgeons are advising and training colleagues in Venezuela through comprehensive care for people affected with this disease.
With more than 250,000 patients treated since 2008, the Good Living for Diabetics Program has the participation of the Cuban Medical Mission, the Center for Genetic Engineering and Biotechnology and the Immuno-Testing Vaccination Research Center, both from Cuba.
(Taken from Prensa Latina)